Clinical Trial Update: A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters [Phase 3]

View source ↗

Summary

A Phase 3 long-term safety and tolerability trial of USL261 (brivaracetam) in patients with seizure clusters has been terminated; results were posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• USL261

Snippet

Sponsor: UCB Biopharma S.P.R.L. | Conditions: Epilepsy | Phase 3 | Status: TERMINATED | Results posted: 2019-01-14